Content sourced from HepMag.com A placebo-controlled study of obeticholic acid showed it improved liver fibrosis with no worsening of non-alcoholic steatohepatitis. An advanced trial of Intercept Pharmaceuticals’ experimental non-alcoholic steatohepatitis (NASH) treatment found it improved liver fibrosis with no worsening …

Article sourced from Zachry WM, et al. Abstract 27. Presented at: American College of Gastroenterology Annual Scientific Meeting; Oct. 5-10, 2018; Philadelphia. PHILADELPHIA — FibroScan screening for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis could significantly improve patient diagnosis and care, …

Content sourced from Hepmag.com As pharmaceutical companies race to develop treatments for NASH, they find one thing is missing: willing test subjects. As the rate of liver disease continues to rise along with the rate of obesity, more than a …